Skip Navigation

Visiting Dana-Farber? See our prescreening and mask requirements.

About the BPDCN Center

  • Andrew Lane, MD, PhD, director of the BPDCN Center, explains the symptoms and diagnosis of BPDCN. The BPDCN Center offers a multidisciplinary approach to care for patients, and focuses on basic and clinical research to better understand BPDCN and improve outcomes.

  • New Patient Appointments

    Make Appointment Online
    Dana-Farber Brigham Cancer Center logo
    US News adult badge - smaller
  • Clinical Trials Questions?



  • At the BPDCN Center at Dana-Farber Brigham Cancer Center, our mission is to combine world-class patient care with leading-edge research – to provide highly effective, personalized treatment options for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). BPDCN is a rare and aggressive hematologic malignancy that affects fewer than 1,000 people each year. Our center is one of the first in the U.S. to focus on care and research for patients with BPDCN.

    As part of Dana-Farber Brigham Cancer Center's Hematologic Oncology Treatment Center, the BPDCN Center is staffed by a multidisciplinary team of medical oncologists, pathologists, dermatologists, and other specialists dedicated to providing exceptional care to patients with this disease.

    About BPDCN

    Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy of the bone marrow and blood that can affect other organs such as the lymph nodes, spleen, central nervous system, and skin. In fact, skin lesions are present in most patients with BPDCN.  These skin lesions are often a deep purple color, and patients often develop multiple lesions. More men than women are diagnosed with BPDCN (~4:1 ratio), and it is most common in patients age 60 years and older.

    Patients with BPDCN demonstrate disease characteristics that are similar to certain types of leukemia or lymphoma. Therefore, an accurate pathologic diagnosis is important for patients to receive the best care. Our hematopathologists are experienced in the techniques and testing necessary to accurately identify BPDCN.

    BPDCN can also evolve from prior myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML), so patients with those diseases and skin lesions should be specifically evaluated for BPDCN.

    Previously referred to as blastic NK cell leukemia and agranular CD4+/CD56+ hematodermic neoplasm, BPDCN was officially named by the World Health Organization in 2008.

    Signs and Symptoms

    Common signs and symptoms of BPDCN include:

    • Deep purple skin lesions
    • Fatigue
    • Fever
    • Night sweats
  • Services and Support at Dana-Farber

    new patient coordinators

    Becoming a Patient

    As a new Dana-Farber patient, find answers to questions about your first visit: what to bring, how to find us, where to park, and how to prepare.

    cover supportive resources brochure

    Support Services and Amenities

    We offer a wide range of services, from financial planning to creative arts to spiritual counsel, to support our patients through their cancer experiences.

    patient rating stars

    How Our Patients Rate Dana-Farber

    See patient satisfaction survey results for different Dana-Farber locations collected by Press Ganey, an independent company experienced in patient satisfaction surveying.